-+ 0.00%
-+ 0.00%
-+ 0.00%
GE HealthCare's Mangaciclanol Phase 2 Results Support Move to Phase 3 MRI Trial
Share
Listen to the news
GE HealthCare's Mangaciclanol Phase 2 Results Support Move to Phase 3 MRI Trial
  • GE HealthCare's Phase 2 results support advancing investigational manganese-based MRI contrast agent mangaciclanol into Phase 3 of the LUMINA trial.
  • The study met its primary endpoint, showing similar overall diagnostic preference to gadobutrol; no safety concerns emerged following mangaciclanol administration.
  • Phase 3 will further evaluate efficacy and safety in detecting and characterizing central nervous system and body lesions.
  • Mangaciclanol has FDA Fast Track designation but remains unapproved, targeting a market of approximately 65 million gadolinium-enhanced MRI procedures annually.
  • Preliminary Phase 2 results will be presented at RSNA in Chicago on December 1, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611190800BIZWIRE_USPR_____20261119_BW117575) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending